Biogen Inc. buy tbackenh
Start price
08.06.21
/
80%
€320.85
Target price
08.06.22
€330.00
Performance (%)
-41.88%
End price
08.06.22
€186.48
Summary
This prediction ended on 08.06.22 with a price of €186.48. The BUY prediction by tbackenh for Biogen Inc. performed very badly with a performance of -41.88%. tbackenh has 80% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Biogen Inc. | -5.741% | -5.741% | -33.178% |
| iShares Core DAX® | -1.670% | -1.001% | 10.864% |
| iShares Nasdaq 100 | -4.184% | -1.145% | 37.458% |
| iShares Nikkei 225® | -4.967% | -5.783% | 18.828% |
| iShares S&P 500 | -2.834% | -0.572% | 25.875% |
According to tbackenh what are the pros and cons of Biogen Inc. for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Differentiated customer and product portfolio
Top 10 in its market
Well known brand
Future proof or reliable business model
Cons
Comments by tbackenh for this prediction
In the thread Biogen Inc. diskutieren
Zulassung der US-amerikanischen Food and Drug Administration für die Alzheimer-Behandlung ADUHELM (Aducanumab) ist genehmigt. Dies sollte frischen Wind bringen. Nach dem > 30% Kurssprung gestern kann allerdings auch zunächst das GAP nach unten geschlossen werden. Langfristiges BUY!
In the thread Trading Biogen Inc.
Die von tbackenh gewählte maximale Laufzeit wurde überschritten